Alliancebernstein L.P. Has $117.21 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Alliancebernstein L.P. trimmed its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 3.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,835,449 shares of the medical device company’s stock after selling 136,999 shares during the quarter. Alliancebernstein L.P. owned about 0.08% of AtriCure worth $117,211,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ATRC. Charles Schwab Investment Management Inc. increased its holdings in shares of AtriCure by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 394,584 shares of the medical device company’s stock valued at $11,064,000 after acquiring an additional 5,812 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of AtriCure by 38.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,053 shares of the medical device company’s stock valued at $394,000 after purchasing an additional 3,880 shares during the period. Captrust Financial Advisors acquired a new stake in shares of AtriCure in the third quarter worth $230,000. State Street Corp boosted its holdings in shares of AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after buying an additional 63,002 shares during the period. Finally, Two Sigma Advisers LP grew its stake in AtriCure by 14.6% in the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock valued at $18,621,000 after buying an additional 84,700 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Up 2.3 %

Shares of ATRC stock opened at $34.13 on Thursday. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The stock has a fifty day moving average price of $37.61 and a 200 day moving average price of $34.10. The stock has a market cap of $1.67 billion, a P/E ratio of -35.93 and a beta of 1.53.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, March 27th. Piper Sandler raised their target price on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Stifel Nicolaus upped their price target on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. JMP Securities restated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a research note on Monday, February 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $51.00 target price on shares of AtriCure in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and an average price target of $49.44.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the transaction, the director now owns 17,828 shares of the company’s stock, valued at $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.20% of the stock is owned by insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.